Securities code: 688185 securities abbreviation: Cansino Biologics Inc(688185) Announcement No.: 2022-004
Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
Announcement of resolutions of the seventh extraordinary meeting of the second board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Convening of board meeting
The seventh interim meeting of the second board of directors of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company (hereinafter referred to as “the company”) was held by means of communication on January 23, 2022. All directors unanimously agreed to waive the notice time requirement of this board meeting. The meeting was presided over by the chairman, Dr. Xuefeng Yu (Yu Xuefeng). There were 12 directors who should attend the meeting and 12 directors who actually attended the meeting. The convening, convening and voting procedures of the meeting comply with the company law of the people’s Republic of China and other laws and regulations, normative documents and the Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) articles of association, which are legal and effective.
2、 Deliberations of the board meeting
After deliberation and voting by the directors attending the meeting, the following resolutions are formed:
(I) the proposal on repurchase of A-Shares of the company by means of centralized bidding transaction was deliberated and adopted. Based on the confidence in the future development prospect of the company and the high recognition of the value of the company, in order to safeguard the interests of the majority of investors, enhance investor confidence, improve the company’s long-term incentive mechanism and fully mobilize the enthusiasm of the company’s managers and core backbone, Improve team cohesion and competitiveness, effectively promote the long-term development of the company, and agree that the company will repurchase shares through centralized bidding transaction with total self owned funds of no less than RMB 150 million (inclusive) and no more than RMB 300 million (inclusive). The shares after this repurchase will be used for the company’s employee stock ownership plan or equity incentive, It is agreed that the board of directors authorizes the management of the company to handle matters related to this share repurchase within the scope of laws and regulations.
Voting results: 12 in favor, 0 against and 0 abstention.
Independent directors have expressed independent opinions.
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) Announcement on repurchase of A-Shares of the company by means of centralized bidding transaction (Announcement No.: 2022-005).
It is hereby announced.
Board of directors of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company January 24, 2022
